Volume 83, Issue 1, Pages (January 2013)

Slides:



Advertisements
Similar presentations
Volume 68, Pages S24-S28 (July 2005)
Advertisements

Volume 83, Issue 2, Pages (February 2013)
Volume 79, Pages S3-S8 (April 2011)
Volume 73, Issue 1, Pages 3-5 (January 2008)
Urinary ammonia and long-term outcomes in chronic kidney disease
Volume 89, Issue 4, Pages (April 2016)
Fibroblast Growth Factor 23 and CKD Prognosis
Mitchell H. Rosner, W. Kline Bolton  Kidney International 
Volume 83, Issue 3, Pages (March 2013)
FGF23 or PTH: which comes first in CKD ?
Volume 78, Pages S10-S21 (August 2010)
Tilman B. Drüeke, Ziad A. Massy  Kidney International 
Volume 64, Issue 6, Pages (December 2003)
FGF23–parathyroid interaction: implications in chronic kidney disease
Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets  David M. Spiegel, Kate Brady  Kidney.
Reassessment of the care of the patient with chronic kidney disease
Volume 79, Pages S24-S27 (April 2011)
Volume 79, Pages S3-S8 (April 2011)
Volume 80, Issue 4, Pages (August 2011)
Jeffrey C. Fink, Glenn M. Chertow  Kidney International 
Volume 76, Pages S50-S99 (August 2009)
The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age  B.O. Eriksen, O.C. Ingebretsen  Kidney International 
Steven G. Coca, Swathi Singanamala, Chirag R. Parikh 
Volume 84, Issue 5, Pages (November 2013)
Volume 78, Issue 9, Pages (November 2010)
Comorbidity and confounding in end-stage renal disease
Proinflammatory effects of iron sucrose in chronic kidney disease
Ten years of progress in our understanding of uremic vascular calcification and disease: a decade summarized in 20 steps  Vincent M. Brandenburg, Markus.
Volume 70, Issue 11, Pages (December 2006)
Volume 79, Pages S20-S23 (April 2011)
Use of vitamin D in chronic kidney disease patients
Volume 78, Issue 10, Pages (November 2010)
Florian Lang, Michael Föller  Kidney International 
Clinical relevance of FGF-23 in chronic kidney disease
Volume 79, Issue 1, Pages (January 2011)
Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.
Volume 80, Issue 5, Pages (September 2011)
Volume 69, Issue 3, Pages (February 2006)
Volume 82, Issue 3, Pages (August 2012)
Volume 68, Pages S24-S28 (July 2005)
Volume 73, Issue 12, Pages (June 2008)
Volume 74, Pages S88-S93 (December 2008)
Volume 82, Issue 12, Pages (December 2012)
Volume 87, Issue 1, Pages (January 2015)
Volume 87, Issue 3, Pages (March 2015)
Volume 68, Issue 3, Pages (September 2005)
Volume 71, Issue 6, Pages (March 2007)
Volume 76, Issue 8, Pages (October 2009)
Volume 76, Issue 8, Pages (October 2009)
A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease  S. Susan Hedayati, Venkata Yalamanchili,
Volume 75, Issue 9, Pages (May 2009)
Fibroblast growth factor 23: the making of a hormone
Volume 79, Issue 12, Pages (June 2011)
Volume 77, Issue 12, Pages (June 2010)
Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients  B. Bammens, P. Evenepoel, H. Keuleers,
Volume 78, Issue 10, Pages (November 2010)
Low triiodothyronine and survival in end-stage renal disease
Volume 80, Issue 10, Pages (November 2011)
Volume 81, Issue 7, Pages (April 2012)
Increased parathyroid expression of klotho in uremic rats
Charles A. Herzog  Kidney International 
The hypothesis that abnormal BH4 metabolism impairs kidney function
Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease  Aquiles Jara, Arnold J. Felsenfeld, Jordi.
Volume 54, Issue 6, Pages (January 1998)
Diagram of the mechanisms involved in limiting the ability of the kidney to maintain the levels of 1,25-dihydroxyvitamin D in chronic kidney disease (CKD).
O.M. Gutiérrez, T. Isakova, D.L. Andress, A. Levin, M. Wolf 
Marta Christov, Harald Jüppner  Kidney International 
Tamara Isakova, Orlando M. Gutiérrez, Myles Wolf  Kidney International 
Ronen Levi, Justin Silver  Kidney International 
Volume 86, Issue 2, Pages (August 2014)
Presentation transcript:

Volume 83, Issue 1, Pages 121-128 (January 2013) Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease  Sarah Seiler, Ming Wen, Heinz J. Roth, Michael Fehrenz, Franziska Flügge, Esther Herath, Anja Weihrauch, Danilo Fliser, Gunnar H. Heine  Kidney International  Volume 83, Issue 1, Pages 121-128 (January 2013) DOI: 10.1038/ki.2012.288 Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 1 Parameters of calcium-phosphate metabolism and renal function. (a) Levels of secreted Klotho (sKlotho), (b) fibroblast growth factor-23 (FGF-23), (c) PTH (parathyroid hormone), (d) and urinary fractional phosphate excretion (FePi) stratified by KDOQI stage, depicted as box plots. Indicated are medians, interquartile ranges (IQR), minimal and maximal values, outliers (defined as values between 1.5 and 3 times IQR, and represented by circles), and extreme values (defined as values more than three times IQR and represented by asterisks). Note: arrows indicate six patients who had FGF-23 values higher than 1200rU/ml. CKD, chronic kidney disease. Kidney International 2013 83, 121-128DOI: (10.1038/ki.2012.288) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 2 Secreted Klotho (sKlotho) levels and event-free survival. Patients were stratified by their plasma sKlotho levels (tertile 1: 278.6–480.3pg/ml, tertile 2: 480.4–620.0pg/ml, tertile 3: 623.9–2130.0pg/ml). Kaplan–Meier analysis with log-rank test did not reveal a significant difference between groups (P=0.336). Kidney International 2013 83, 121-128DOI: (10.1038/ki.2012.288) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 3 Fibroblast growth factor-23 (FGF-23) levels and event-free survival. Patients were stratified by their plasma FGF-23 levels (tertile 1: 14.8–71.2rU/ml, tertile 2: 71.6–136.8rU/ml, tertile 3: 138.1–7273.9rU/ml). Kaplan–Meier analysis with log-rank test revealed a significant difference between groups (P<0.001). Kidney International 2013 83, 121-128DOI: (10.1038/ki.2012.288) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 4 Linearity-of-dilution experiment. Recombinant human α-Klotho was diluted to yield a concentration of 1250ng/l. Different dilutions of the sample were tested (sample:diluent ratio: 1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2, and 9:1). Kidney International 2013 83, 121-128DOI: (10.1038/ki.2012.288) Copyright © 2013 International Society of Nephrology Terms and Conditions